Intestinal alkaline phosphatase prevents antibiotic-induced susceptibility to enteric pathogens

Annals of Surgery

Volumn 259, Issue 4, 2014, Pages 715-722

  Alam, Sayeda Nasrin ^a   Yammine, Halim ^a   Moaven, Omeed ^a   Ahmed, Rizwan ^a   Moss, Angela K ^a   Biswas, Brishti ^a   Muhammad, Nur ^a   Biswas, Rakesh ^a   Raychowdhury, Atri ^a   Kaliannan, Kanakaraju ^a   Ghosh, Sathi ^a   Ray, Madhury ^a   Hamarneh, Sulaiman R ^a   Barua, Soumik ^a   Malo, Nondita S ^a   Bhan, Atul K ^a   Malo, Madhu S ^a   Hodin, Richard A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Antibiotic associated diarrhea; bacterial pathogenesis; Clostridium difficile associated disease; microbiotal homeostasis; salmonellosis

Indexed keywords

ALKALINE PHOSPHATASE; ALKALINE PHOSPHATASE INTESTINE ISOENZYME; CLINDAMYCIN; DRINKING WATER; INTESTINE ENZYME; STREPTOMYCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COLONY FORMING UNIT; CONTROLLED STUDY; FEMALE; INFECTION PREVENTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SALMONELLA TYPHIMURIUM; SALMONELLOSIS; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ALKALINE PHOSPHATASE; ANIMALS; ANTI-BACTERIAL AGENTS; BIOLOGICAL MARKERS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COLON; DIARRHEA; FEMALE; GASTROINTESTINAL AGENTS; INTESTINAL MUCOSA; MICE; MICE, INBRED C57BL; SALMONELLA INFECTIONS; SALMONELLA TYPHIMURIUM; STREPTOMYCIN; TREATMENT OUTCOME;

EID: 84895918344     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e31828fae14     Document Type: Article

References (41)

1. Miller CP, Bohnhoff M. Changes in the mouse's enteric microflora associated with enhanced susceptibility to Salmonella infection following streptomycin treatment. J Infect Dis. 1963;113:59-66.
2. Van Der Waaij D, Berghuis-de Vries JM, Lekkerkerk L-v. Colonization resistance of the digestive tract in conventional and antibiotic-treated mice. J Hyg (Lond). 1971;69(3):405-411.
3. Sekirov I, Tam NM, Jogova M, et al. Antibiotic-induced perturbations of the intestinal microbiota alter host susceptibility to enteric infection. Infect Immun. 2008;76(10):4726-4736.
4. Chen X, Katchar K, Goldsmith JD, et al. A mouse model of Clostridium difficile-associated disease. Gastroenterology. 2008;135(6):1984-1992.
5. Glynn MK, Reddy V, Hutwagner L, et al. Prior antimicrobial agent use increases the risk of sporadic infections with multidrug-resistant Salmonella enterica serotype Typhimurium: A FoodNet case-control study, 1996-1997. Clin Infect Dis. 2004;38(Suppl 3):S227-S236.
6. Kachrimanidou M, Malisiovas N. Clostridium difficile infection: A comprehensive review. Crit Rev Microbiol. 2011;37:178-187.
7. Vaishnavi C. Clinical spectrum and pathogenesis of Clostridium difficileassociated diseases. Indian J Med Res. 2010;131:487-99.
8. Hookman P, Barkin JS. Clostridium difficile-associated infection, diarrhea and colitis. World J Gastroenterol. 2009;15:1554-1580.
9. Malo MS,Alam SN, Mostafa G, et al. Intestinal alkaline phosphatase preserves the normal homeostasis of gut microbiota. Gut. 2010;59:1476-1484.
10. Lankowski AJ, Hohmann EL. Killed but metabolically active Salmonella Typhimurium: Application of a new technology to an old vector. J Infect Dis. 2007;195:1203-1211.
11. Baykov AA, Kasho VN, Avaeva SM. Inorganic pyrophosphatase as a label in heterogeneous enzyme immunoassay. Anal Biochem. 1988;171:271-276.
12. Kelly CP, Becker S, Linevsky JK, et al. Neutrophil recruitment in Clostridium difficile toxin A enteritis in the rabbit. J Clin Invest. 1994;93: 1257-1265.
13. Krawisz JE, Sharon P, Stenson WF. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology. 1984;87:1344-1350.
14. Ramasamy S, Nguyen DD, Eston MA, et al. Intestinal alkaline phosphatase has beneficial effects in mouse models of chronic colitis. Inflamm Bowel Dis. 2011;17:532-542.
15. Ebrahimi F, Malo MS,Alam SN, et al.Local peritoneal irrigationwith intestinal alkaline phosphatase is protective against peritonitis in mice. J Gastrointest Surg. 2011;15:860-869.
16. Siegmund B, Lehr HA, Fantuzzi G, Dinarello CA. IL-1 beta-converting enzyme (caspase-1) in intestinal inflammation. Proc Natl Acad Sci USA 2001;98:13249-13254.
17. Cotter PD. Small intestine and microbiota. Curr Opin Gastroenterol. 2011;27(2):99-105.
18. Ley RE, Lozupone CA, Hamady M, et al. Worlds within worlds: Evolution of the vertebrate gut microbiota. Nat Rev Microbiol. 2008;6:776-788.
19. Marchesi J, Shanahan F. The normal intestinal microbiota. Curr Opin Infect Dis. 2007;20:508-513.
20. Backhed F, Ley RE, Sonnenburg JL, et al. Host-bacterial mutualism in the human intestine. Science. 2005;307:1915-1920.
21. Bartlett JG. Clostridium difficile-associated enteric disease. Curr Infect Dis Rep. 2002;4:477-483.
22. McFarland LV. Antibiotic-associated diarrhea: Epidemiology, trends and treatment. Future Microbiol. 2008;3:563-578.
23. Schroeder MS. Clostridium difficile-associated diarrhea. Am Fam Phys. 2005;71:921-928.
24. Brenchley JM, Price DA, Douek DC. HIV disease: Fallout from a mucosal catastrophe Nat Immunol. 2006;7:235-239.
25. Ley SH, Harris SB, Connelly PW, et al. Association of apolipoprotein B with incident type 2 diabetes in an aboriginal Canadian population. Clin Chem. 2010;56:666-670.
26. Turnbaugh PJ, Gordon JI. The core gut microbiome, energy balance and obesity. J Physiol. 2009;587:4153-4158.
27. Sussman NL, Eliakim R, Rubin D, et al. Intestinal alkaline phosphatase is secreted bidirectionally from villous enterocytes.AmJ Physiol. 1989;257:G14-G23.
28. Chen KT, Malo MS, Moss AK, et al. Identification of specific targets for the gut mucosal defense factor intestinal alkaline phosphatase. Am J Physiol Gastrointest Liver Physiol. 2010;299:G467-G475.
29. Moss WW, Webster WA. A numerical taxonomic study of a group of selected strongylates (Nematoda). Syst Zool. 1969;18:423-443.
30. Narisawa S, Huang L, Iwasaki A, et al. Accelerated fat absorption in intestinal alkaline phosphatase knockout mice.Mol Cell Biol. 2003;23:7525-7530.
31. Bates JM, Akerlund J, Mittge E, et al. Intestinal alkaline phosphatase detoxifies lipopolysaccharide and prevents inflammation in zebrafish in response to the gut microbiota. Cell Host Microbe. 2007;2:371-382.
32. Goldberg RF, AustenWG Jr, Zhang X, et al. Intestinal alkaline phosphatase is a gut mucosal defense factor maintained by enteral nutrition. Proc Natl Acad Sci USA. 2008;105:3551-3556.
33. Chen KT, Malo MS, Beasley-Topliffe LK, et al. A role for intestinal alkaline phosphatase in the maintenance of local gut immunity. Dig Dis Sci. 2011;56:1020-1027.
34. Beumer C,WulferinkM, Raaben W, et al. Calf intestinal alkaline phosphatase, a novel therapeutic drug for lipopolysaccharide (LPS)-mediated diseases, attenuates LPS toxicity in mice and piglets. J Pharmacol Exp Ther. 2003;307:737-744.
35. Lukas M, Drastich P, Konecny M, et al. Exogenous alkaline phosphatase for the treatment of patients with moderate to severe ulcerative colitis. Inflamm Bowel Dis. 2010;16:1180-1186.
36. Hallstrom K, McCormickBA. Salmonella interactionwith and passage through the intestinal mucosa: Through the lens of the organism. Front Microbiol. 2011;2:88.
37. Crump JA, Mintz ED. Global trends in typhoid and paratyphoid Fever. Clin Infect Dis. 2010;50:241-246.
38. Wollin R. A study of invasiveness of different Salmonella serovars based on analysis of the Enter-net database. Euro Surveill. 2007;12. Article 3.
39. Camacho-Ortiz A, Ponce-de-LeonA, Sifuentes-Osornio J. Clostridum difficileassociated disease in Latin America. Gac Med Mex. 2009;145:223-229.
40. McFarland LV. Risk factor for antibiotic-associated diarrhea. A review of the literature. Ann Med Intern (Paris). 1998;149:261-266.
41. O'Brien JA, Lahue BJ, Caro JJ, et al. The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: Clinical and economic consequences. Infect Control Hosp Epidemiol. 2007;28: 1219-1227.